Three-year outcomes of patients with non-valvular atrial fibrillation: the COOL-AF registry

[1]

Gibbs H, Freedman B, Rosenqvist M, et al. Clinical outcomes in asymptomatic and symptomatic atrial fibrillation presentations in GARFIELD-AF: Implications for AF Screening. Am J Med 2021; 134: 893-901 e811.

[2] Bassand JP, Accetta G, Al Mahmeed W, et al. Risk factors for death, stroke, and bleeding in 28, 628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One 2018; 13: e0191592. doi: 10.1371/journal.pone.0191592 [3] Burdett P, Lip GYH. Atrial fibrillation in the united kingdom: predicting costs of an emerging epidemic recognising and forecasting the cost drivers of atrial fibrillation-related costs. Eur Heart J Qual Care Clin Outcomes 2022; 8: 187−194. doi: 10.1093/ehjqcco/qcaa093 [4] Piccini JP, Simon DN, Steinberg BA, et al. Differences in clinical and functional outcomes of atrial fibrillation in women and men: two-year results from the ORBIT-AF registry. JAMA Cardiol 2016; 1: 282−291. doi: 10.1001/jamacardio.2016.0529 [5] Koretsune Y, Etoh T, Katsuda Y, et al. Risk Profile and 1-year outcome of newly diagnosed atrial fibrillation in Japan- Insights From GARFIELD-AF. Circ J 2018; 83: 67−74. doi: 10.1253/circj.CJ-18-0655 [6] Fox KAA, Virdone S, Bassand JP, et al. Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry. BMJ Open 2022; 12: e049933. doi: 10.1136/bmjopen-2021-049933 [7]

Kim HK, Tantry US, Smith SC Jr, et al. The east asian paradox:an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121: 422−432.

[8] Lip GY, Wang KL, Chiang CE. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: time for a reappraisal. Int J Cardiol 2015; 180: 246−254. doi: 10.1016/j.ijcard.2014.11.182 [9] Wang KL, Lip GY, Lin SJ, Chiang CE. Non-vitamin k antagonist oral anticoagulants for stroke prevention in asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 2015; 46: 2555−2561. doi: 10.1161/STROKEAHA.115.009947 [10] An Y, Ogawa H, Yamashita Y, et al. Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes 2019; 5: 35−42. doi: 10.1093/ehjqcco/qcy033 [11] Heijman J, Guichard JB, Dobrev D, Nattel S. Translational challenges in atrial fibrillation. Circ Res 2018; 122: 752−773. doi: 10.1161/CIRCRESAHA.117.311081 [12] Salih M, Abdel-Hafez O, Ibrahim R, Nair R. Atrial fibrillation in the elderly population: Challenges and management considerations. J Arrhythm 2021; 37: 912−921. doi: 10.1002/joa3.12580 [13]

Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 42: 373−498.

[14] January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74: 104−132. doi: 10.1016/j.jacc.2019.01.011 [15] Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST Guideline and Expert Panel Report. Chest 2018; 154: 1121−1201. doi: 10.1016/j.chest.2018.07.040 [16] Chao TF, Joung B, Takahashi Y, et al. 2021 focused update consensus guidelines of the asia pacific heart rhythm society on stroke prevention in atrial fibrillation: executive summary. Thromb Haemost 2022; 122: 20−47. doi: 10.1055/s-0041-1739411 [17] Bahuleyan CG, Namboodiri N, Jabir A, et al. One-year clinical outcome of patients with nonvalvular atrial fibrillation: Insights from KERALA-AF registry. Indian Heart J 2021; 73: 56−62. doi: 10.1016/j.ihj.2020.11.152 [18] Krittayaphong R, Winijkul A, Methavigul K, et al. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study. BMC Cardiovasc Disord 2018; 18: 174. doi: 10.1186/s12872-018-0911-4 [19] Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692−694. doi: 10.1111/j.1538-7836.2005.01204.x [20] Ogawa H, Hamatani Y, Doi K, et al. Sex-related differences in the clinical events of patients with atrial fibrillation—The Fushimi AF Registry. Circ J 2017; 81: 1403−1410. doi: 10.1253/circj.CJ-17-0071 [21] Chan YH, Lee HF, See LC, et al. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chest 2019; 156: 529−543. doi: 10.1016/j.chest.2019.04.108 [22] Krittayaphong R, Boonyapiphat T, Wongvipaporn C, et al. Age-related clinical outcomes of patients with non-valvular atrial fibrillation: insights from the COOL-AF Registry. Clin Interv Aging 2021; 16: 707−719. doi: 10.2147/CIA.S302389 [23] Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. Stroke 2015; 46: 23−30. doi: 10.1161/STROKEAHA.114.006476 [24] Shen AY, Yao JF, Brar SS, et al. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation. J Am Coll Cardiol 2007; 50: 309−315. doi: 10.1016/j.jacc.2007.01.098 [25] Chao TF, Chen SA, Ruff CT, et al. Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 2019; 40: 1518−1527. doi: 10.1093/eurheartj/ehy807 [26] Yamashita Y, Hamatani Y, Esato M, et al. Clinical characteristics and outcomes in extreme elderly (age >/= 85 years) japanese patients with atrial fibrillation: the Fushimi AF registry. Chest 2016; 149: 401−412. doi: 10.1378/chest.15-1095 [27] Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14: 627−628. doi: 10.1038/nrcardio.2017.153 [28] Potpara TS, Lip GYH, Blomstrom-Lundqvist C, et al. The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thromb Haemost 2021; 121: 270−278. doi: 10.1055/s-0040-1716408 [29] Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the ‘Atrial Fibrillation Better Care’ Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic Review and Meta-Analysis of 285,000 Patients. Thromb Haemost 2022; 122: 406−414. doi: 10.1055/a-1515-9630 [30] Yoon M, Yang PS, Jang E, et al. Improved population-based clinical outcomes of patients with atrial fibrillation by compliance with the simple ABC (Atrial Fibrillation Better Care) Pathway for Integrated Care Management: A Nationwide Cohort Study. Thromb Haemost 2019; 119: 1695−1703. doi: 10.1055/s-0039-1693516 [31] Rasmussen PV, Pallisgaard JL, Hansen ML, et al. Treatment of older patients with atrial fibrillation by morbidity burden. Eur Heart J Qual Care Clin Outcomes 2022; 8: 23−30. doi: 10.1093/ehjqcco/qcaa070 [32] Proietti M, Marzona I, Vannini T, et al. Long-term relationship between atrial fibrillation, multimorbidity and oral anticoagulant drug use. Mayo Clin Proc 2019; 94: 2427−2436. doi: 10.1016/j.mayocp.2019.06.012 [33] An Y, Ogawa H, Esato M, et al. Age-dependent prognostic impact of paroxysmal versus sustained atrial fibrillation on the incidence of cardiac death and heart failure hospitalization (the Fushimi AF Registry). Am J Cardiol 2019; 124: 1420−1429. doi: 10.1016/j.amjcard.2019.07.048 [34] Apiyasawat S, Kornbongkotmas S, Chichareon P, et al. Mortality risk and temporal patterns of atrial fibrillation in the nationwide registry. J Arrhythm 2021; 37: 1434−1442. doi: 10.1002/joa3.12643

留言 (0)

沒有登入
gif